They plan to make decision by mid-July.
The Food and Drug Administration is facing a critical decision: whether to offer new COVID-19 booster shots this fall that are modified to better match recent mutations in the coronavirus.
Moderna and Pfizer have released updated shots against the omicron variant, and advisers to the FDA will debate this week if it is time to make a switch, setting the stage for similar moves by other companies
“This is science at its toughest,” Center for Biologics Evaluation and Research Director Peter Marks said, adding that a final decision is expected within days of the advisory panel’s recommendation.
Dr. Anthony Fauci told Congress last week, “The virus is changing and we need to keep up with it.”
As the Lord Leads, Pray with Us…
- For Director Marks to seek God’s wisdom as he heads FDA’s Center for Biologics and Research.
- For Commissioner Califf as he determines the priorities of the FDA.
- For scientists and researchers evaluating the effectiveness of the COVID vaccines in relation to the mutations.
Sources: Newsmax, Associated Press
